Drug intelligence / Profile preview

LEAD-462

Development stage: Unknown
Lead developer: Leadartis
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

LEAD-462 is a bispecific antibody drug candidate developed by LeadArtis. It is designed to function as a tumor necrosis factor receptor (TNFR) agonist and tumor-associated antigen (TAA) inhibitor, with additional antibody-dependent cell-mediated cytotoxicity (ADCC) effects. The drug aims to stimulate T lymphocytes and enhance immune responses against cancer cells by targeting both TNFRs and TAAs. Its primary therapeutic focus includes neoplasms, digestive system disorders, and respiratory diseases, with active indications in breast cancer, colorectal cancer, and kidney neoplasms. As of the latest update in March 2025, LEAD-462 remains in the discovery phase of development[1][2].

Targets

TNFR (TNF receptor family)MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on LEAD-462.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAD-462.

Explore the full profile